U.S. President Donald Trump, U.S. Well being and Human Providers (HHS) Secretary Robert F. Kennedy, Jr., Dr. Mehmet Oz, Administrator for the Facilities for Medicare & Medicaid Providers, David Sacks, AI & Crypto Czar and Amy Gleason, Performing Administrator, Division of Authorities Effectivity (DOGE) attend the “Making Well being Expertise Nice Once more” occasion within the East Room on the White Home in Washington, D.C., U.S., July 30, 2025.
Evelyn Hockstein | Reuters
President Donald Trump on Thursday mentioned he requested main pharmaceutical firms to take steps to chop U.S. drug costs throughout the subsequent 60 days.
On Fact Social on Thursday, Trump posted particular person letters he despatched 17 drugmakers, together with Eli Lilly, GSK, Pfizer, Regeneron, Merck, and Novo Nordisk.
Trump threatened to “deploy ever device in our arsenal to guard American households from continued abusive drug pricing practices” if firms refuse to conform.
The letters come after Trump in Could signed an government order reviving a controversial plan, often known as the “most favored nation” coverage, that goals to slash drug costs by tying the costs of some medicines within the U.S. to the considerably decrease ones overseas. It was Trump’s chief executive effort to attempt to rein in U.S. prescription drug costs, that are two to three times higher on average than those in different developed nations – and as much as 10 occasions greater than in sure nations, based on the Rand Corp., a public coverage suppose tank.
Within the letters on Thursday, Trump mentioned drugmakers have proposed potential options for prime U.S. drug costs. However he mentioned these proposals “promised extra of the identical: shifting blame and requesting coverage modifications that will lead to billions of {dollars} in handouts to the trade.”
He mentioned transferring ahead, he’ll solely settle for commitments from drugmakers that present “American households instant aid from the vastly inflated drug costs and an finish to the free experience of American innovation by European and different developed nations.” Trump mentioned a collaborative effort in the direction of decreasing U.S. drug costs can be the “only path” for firms, the federal government and sufferers.
A spokesperson for PhRMA, the trade’s largest lobbying group, didn’t instantly reply to a request for remark.
Drugmakers are additionally bracing for the president’s deliberate tariffs on prescription drugs imported into the U.S.
That is breaking information. Please refresh for updates.